{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T02:00:54Z","timestamp":1793412054871,"version":"4.5.0"},"reference-count":41,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2025,4,1]]},"abstract":"\n Importance<\/jats:title>\n Spontaneous reports have indicated that montelukast increases the risk of neuropsychiatric adverse events, and the US Food and Drug Administration added a boxed warning about these risks in 2020. However, the potential mechanism is not well understood, and the observational evidence is scarce, particularly in children.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To assess the potential association between the use of montelukast and the risk of neuropsychiatric adverse events in children and adolescents.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n This nationwide register-based cohort study used data from Sweden from January 1, 2007, to November 30, 2021. Participants included children aged 6 to 17 years who used montelukast and long-acting \u03b2-agonists (LABA). Data analysis was performed from December 2023 to April 2024.<\/jats:p>\n <\/jats:sec>\n \n Exposure<\/jats:title>\n Montelukast vs LABA.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n The primary outcome, any neuropsychiatric adverse event, was a composite of secondary outcomes, including anxiety; depression; sleep-related disorders; suicide and suicidal actions; disrupted control of activity, attention, and behavior; and confusion and psychotic-like symptoms. Outcomes were defined on the basis of diagnosis codes and dispensings of prescription drugs for specific neuropsychiatric symptoms. Patients were followed up from drug initiation to discontinuation, and treatment and censoring weights were used to adjust for potential confounding on baseline and selection bias from informative censoring. Pooled logistic regression was used to estimate hazard ratios (HRs).<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n The final cohort included 74 291 children (mean [SD] age, 12.3 [3.3] years; 35\u202f446 female [47.7%]); 26\u202f462 used montelukast and 47\u202f829 used LABA. During a mean (SD) follow-up of 5.8 (3.2) months, 310 neuropsychiatric adverse events in the montelukast patients and 566 events in the LABA patients were identified. In the weighted cohort, the incidence rates of neuropsychiatric adverse events were 2.39 per 100 patient-years among the montelukast users and 2.41 per 100 patient-years among the LABA users. This translated to a weighted HR of 0.99 (95% CI, 0.84-1.16). No substantial differences were observed between the montelukast and LABA patients when analyzing the risk of specific neuropsychiatric adverse events: the HRs were 0.79 (95% CI, 0.54-1.14) for anxiety; 1.16 (95% CI, 0.70-1.95) for depression; 0.93 (95% CI, 0.76-1.13) for sleep-related disorders; 1.31 (95% CI, 0.64-2.69) for suicide and suicidal actions; 1.27 (95% CI, 0.84-1.90) for disrupted control of activity, attention, and behavior; and 0.51 (95% CI, 0.05-5.53) for confusion and psychotic-like symptoms. The risk of the primary outcome was consistent over subgroups and a range of sensitivity analyses.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this large study of children and adolescents based on data from routine clinical practice, there was no association between use of montelukast and the risk of neuropsychiatric adverse events. In aggregation with other robust observational studies, these results can inform the management of asthma and allergic rhinitis in this patient group.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamapediatrics.2024.5429","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T11:08:10Z","timestamp":1737457690000},"page":"418","source":"Crossref","is-referenced-by-count":28,"title":["Montelukast Use and the Risk of Neuropsychiatric Adverse Events in Children"],"prefix":"10.1001","volume":"179","author":[{"given":"Viktor","family":"Wintzell","sequence":"first","affiliation":[{"name":"Clinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Brenner","sequence":"additional","affiliation":[{"name":"Centre for Pharmacoepidemiology, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden"},{"name":"Stockholm Health Care Services, Region Stockholm, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Halldner","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Department of Clinical Sciences, Child and Adolescent Psychiatry, Umea University, Umea, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Rhedin","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Sachs\u2019 Children and Youth Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Gong","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catarina","family":"Almqvist","sequence":"additional","affiliation":[{"name":"Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden"},{"name":"Pediatric Allergy and Pulmonology Unit at Astrid Lindgren Children\u2019s Hospital, Karolinska University Hospital, Stockholm, Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"2","key":"poi240095r6","first-page":"64","article-title":"Joint statement on FDA investigation of Singulair from the ACAAI and AAAAI.","volume":"40","year":"2008","journal-title":"Eur Ann Allergy Clin Immunol"},{"issue":"2","key":"poi240095r7","doi-asserted-by":"publisher","first-page":"e34","DOI":"10.1093\/pch\/17.5.e34","article-title":"Prevalence of hypothalamic-pituitary-adrenal axis suppression in children treated for asthma with inhaled corticosteroid.","volume":"17","author":"Smith","year":"2012","journal-title":"Paediatr Child Health"},{"key":"poi240095r8","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2022.121056","article-title":"The mechanisms underlying montelukast\u2019s neuropsychiatric effects: new insights from a combined metabolic and multiomics approach.","volume":"310","author":"Marques","year":"2022","journal-title":"Life Sci"},{"key":"poi240095r9","doi-asserted-by":"publisher","first-page":"8466","DOI":"10.1038\/ncomms9466","article-title":"Structural and functional rejuvenation of the aged brain by an approved anti-asthmatic drug.","volume":"6","author":"Marschallinger","year":"2015","journal-title":"Nat Commun"},{"issue":"4","key":"poi240095r10","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.jaci.2009.08.010","article-title":"Reports of suicidality in clinical trials of montelukast.","volume":"124","author":"Philip","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"poi240095r11","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.jaci.2009.08.011","article-title":"Analysis of behavior-related adverse experiences in clinical trials of montelukast.","volume":"124","author":"Philip","year":"2009","journal-title":"J Allergy Clin Immunol"},{"issue":"1","key":"poi240095r12","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.jaip.2020.07.052","article-title":"Risk of psychiatric adverse events among montelukast users.","volume":"9","author":"Sansing-Foster","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"4","key":"poi240095r13","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/pds.3758","article-title":"Exploring the possible association between montelukast and neuropsychiatric events among children with asthma: a matched nested case-control study.","volume":"24","author":"Ali","year":"2015","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"poi240095r14","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jpeds.2019.02.009","article-title":"Montelukast and neuropsychiatric events in children with asthma: a nested case-control study.","volume":"209","author":"Glockler-Lauf","year":"2019","journal-title":"J Pediatr"},{"issue":"169","key":"poi240095r15","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1183\/16000617.0079-2023","article-title":"Neuropsychiatric events associated with montelukast in patients with asthma: a systematic review.","volume":"32","author":"Lo","year":"2023","journal-title":"Eur Respir Rev"},{"issue":"6","key":"poi240095r17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1600-0447.2011.01747.x","article-title":"Validity of bipolar disorder hospital discharge diagnoses: file review and multiple register linkage in Sweden.","volume":"124","author":"Sellgren","year":"2011","journal-title":"Acta Psychiatr Scand"},{"issue":"1","key":"poi240095r18","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1186\/s12888-020-02644-7","article-title":"Validity and reliability of social anxiety disorder diagnoses in the Swedish National Patient Register.","volume":"20","author":"Vilaplana-P\u00e9rez","year":"2020","journal-title":"BMC Psychiatry"},{"issue":"3","key":"poi240095r19","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1016\/S2215-0366(14)00128-X","article-title":"Depression and violence: a Swedish population study.","volume":"2","author":"Fazel","year":"2015","journal-title":"Lancet Psychiatry"},{"issue":"7","key":"poi240095r20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0041280","article-title":"Autism spectrum disorders in the Stockholm Youth Cohort: design, prevalence and validity.","volume":"7","author":"Idring","year":"2012","journal-title":"PLoS One"},{"key":"poi240095r21","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1186\/1471-2458-11-450","article-title":"External review and validation of the Swedish national inpatient register.","volume":"11","author":"Ludvigsson","year":"2011","journal-title":"BMC Public Health"},{"issue":"14","key":"poi240095r22","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1056\/NEJMsm1605385","article-title":"Per-protocol analyses of pragmatic trials.","volume":"377","author":"Hern\u00e1n","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"poi240095r23","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1177\/1740774511420743","article-title":"Beyond the intention-to-treat in comparative effectiveness research.","volume":"9","author":"Hern\u00e1n","year":"2012","journal-title":"Clin Trials"},{"key":"poi240095r24","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-067554","article-title":"Neuropsychiatric reactions with the use of montelukast.","volume":"376","author":"Ekhart","year":"2022","journal-title":"BMJ"},{"issue":"5","key":"poi240095r25","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology.","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"issue":"1","key":"poi240095r26","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1093\/aje\/kwy201","article-title":"Addressing extreme propensity scores via the overlap weights.","volume":"188","author":"Li","year":"2019","journal-title":"Am J Epidemiol"},{"issue":"5","key":"poi240095r27","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men.","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"issue":"6","key":"poi240095r28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1111\/j.1365-2125.2011.04037.x","article-title":"Benefits and strengths of the disproportionality analysis for identification of adverse drug reactions in a pharmacovigilance database.","volume":"72","author":"Montastruc","year":"2011","journal-title":"Br J Clin Pharmacol"},{"key":"poi240095r29","article-title":"Spontaneous reporting in pharmacovigilance: strengths, weaknesses and recent methods of analysis.","author":"Kasliwal","journal-title":"J Clin Prev Cardiol."},{"issue":"9","key":"poi240095r30","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1111\/cea.14207","article-title":"Paediatric asthma and non-allergic comorbidities: a review of current risk and proposed mechanisms.","volume":"52","author":"Brew","year":"2022","journal-title":"Clin Exp Allergy"},{"issue":"5","key":"poi240095r31","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1097\/EDE.0000000000001521","article-title":"Selection of comparator group in observational drug safety studies: alternatives to the active comparator new user design.","volume":"33","author":"Wintzell","year":"2022","journal-title":"Epidemiology"},{"issue":"5","key":"poi240095r32","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.02467-2021","article-title":"Leukotriene receptor antagonists and risk of neuropsychiatric events in children, adolescents and young adults: a self-controlled case series.","volume":"60","author":"Park","year":"2022","journal-title":"Eur Respir J"},{"issue":"6","key":"poi240095r33","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1111\/joim.12186","article-title":"Use of self-controlled designs in pharmacoepidemiology.","volume":"275","author":"Hallas","year":"2014","journal-title":"J Intern Med"},{"issue":"2","key":"poi240095r34","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1183\/13993003.00148-2017","article-title":"Neuropsychiatric adverse drug reactions in children initiated on montelukast in real-life practice.","volume":"50","author":"Benard","year":"2017","journal-title":"Eur Respir J"},{"issue":"3","key":"poi240095r35","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1080\/02770903.2020.1861626","article-title":"Neuropsychiatric adverse drug reactions induced by montelukast impair the quality of life in children with asthma.","volume":"59","author":"Yilmaz Bayer","year":"2022","journal-title":"J Asthma"},{"issue":"9","key":"poi240095r36","doi-asserted-by":"publisher","first-page":"990","DOI":"10.3109\/02770903.2013.823445","article-title":"Antidepressant medication dispensing among montelukast initiators.","volume":"50","author":"Zhou","year":"2013","journal-title":"J Asthma"},{"issue":"5","key":"poi240095r37","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.13643","article-title":"Analysis of neuropsychiatric diagnoses after montelukast initiation.","volume":"5","author":"Paljarvi","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"2","key":"poi240095r38","doi-asserted-by":"publisher","first-page":"368","DOI":"10.1016\/j.jaci.2012.04.035","article-title":"Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study.","volume":"130","author":"Schumock","year":"2012","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"poi240095r39","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1027\/0227-5910\/a000391","article-title":"Incidence rates of deliberate self-harm in Denmark 1994-2011.","volume":"37","author":"Reuter Morthorst","year":"2016","journal-title":"Crisis"},{"issue":"11","key":"poi240095r40","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009120","article-title":"Are suicide deaths under-reported? nationwide re-evaluations of 1800 deaths in Scandinavia.","volume":"5","author":"T\u00f8llefsen","year":"2015","journal-title":"BMJ Open"},{"key":"poi240095r41","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1186\/s12889-016-3135-5","article-title":"Accidents and undetermined deaths: re-evaluation of nationwide samples from the Scandinavian countries.","volume":"16","author":"T\u00f8llefsen","year":"2016","journal-title":"BMC Public Health"},{"key":"poi240095r1","unstructured":"Global Initiative for Asthma. Global strategy for asthma management and prevention. 2022. Accessed December 9, 2024. http:\/\/www.ginasthma.org"},{"key":"poi240095r2","unstructured":"Socialstyrelsens statistikdatabas. L\u00e4kemedel. 2023. Accessed September 1, 2023. https:\/\/www.socialstyrelsen.se\/statistik-och-data\/statistik\/statistikdatabasen\/"},{"key":"poi240095r3","unstructured":"US Food and Drug Administration. FDA requires Boxed Warning about serious mental health side effects for asthma and allergy drug montelukast (Singulair); advises restricting use for allergic rhinitis. March 4, 2020. Accessed December 9, 2024. https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-boxed-warning-about-serious-mental-health-side-effects-asthma-and-allergy-drug"},{"key":"poi240095r4","unstructured":"US Food and Drug Administration. Early communication about an ongoing safety review of montelukast (Singulair). 2008. Accessed December 13, 2024. https:\/\/wayback.archive-it.org\/7993\/20170112033551\/http:\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm070618.htm"},{"key":"poi240095r5","unstructured":"US Food and Drug Administration. Updated information on leukotriene inhibitors: montelukast (marketed as Singulair), zafirlukast (marketed as Accolate), and zileuton (marketed as Zyflo and Zyflo CR). 2009. Accessed December 13, 2024. https:\/\/wayback.archive-it.org\/7993\/20170111080414\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/PostmarketDrugSafetyInformationforPatientsandProviders\/DrugSafetyInformationforHeathcareProfessionals\/ucm165489.htm"},{"key":"poi240095r16","unstructured":"Scottish Intercollegiate Guidelines Network BTS. British guideline on the management of asthma. 2019. Accessed December 9, 2024. https:\/\/www.sign.ac.uk\/our-guidelines\/british-guideline-on-the-management-of-asthma\/"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2829444\/jamapediatrics_wintzell_2025_oi_240095_1743626882.94312.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T15:52:09Z","timestamp":1744041129000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2829444"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,1]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2024.5429","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,1]]}}}